Roche Evades Cancer Study Stock-Drop Suit For Second Time
Law360 (April 3, 2019, 9:25 PM EDT) -- Swiss pharmaceutical company Roche Holding AG escaped, for the second time, a proposed class action accusing it and four executives of misleading investors about the results of a breast cancer study after a New Jersey federal judge dismissed the suit Wednesday.
U.S. District Judge Anne E. Thompson found that named plaintiff Thomas Biondolillo failed to present specific enough claims in his newly amended complaint that Roche made material misstatements about the results of its APHINITY Phase III study, which tested the effectiveness of combining two cancer medications with chemotherapy.
After dismissing Biondolillo's previous complaint in September for failure to state a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!